Luye Pharma Group Ltd. LUP.F Stock
Luye Pharma Group Ltd. Price Chart
Luye Pharma Group Ltd. LUP.F Financial and Trading Overview
Luye Pharma Group Ltd. stock price | 0.33 EUR |
Previous Close | 0.4 EUR |
Open | 0.4 EUR |
Bid | 0.42 EUR x 770000 |
Ask | 0.43 EUR x 770000 |
Day's Range | 0.42 - 0.42 EUR |
52 Week Range | 0.24 - 0.51 EUR |
Volume | 130 EUR |
Avg. Volume | 155 EUR |
Market Cap | 1.56B EUR |
Beta (5Y Monthly) | 0.983141 |
PE Ratio (TTM) | 20.800001 |
EPS (TTM) | 0.02 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | June 29, 2020 |
1y Target Est | N/A |
LUP.F Valuation Measures
Enterprise Value | 5.98B EUR |
Trailing P/E | 20.800001 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.26160893 |
Price/Book (mrq) | 0.1450994 |
Enterprise Value/Revenue | 1 |
Enterprise Value/EBITDA | 4.197 |
Trading Information
Luye Pharma Group Ltd. Stock Price History
Beta (5Y Monthly) | 0.983141 |
52-Week Change | 42.75% |
S&P500 52-Week Change | 20.43% |
52 Week High | 0.51 EUR |
52 Week Low | 0.24 EUR |
50-Day Moving Average | 0.42 EUR |
200-Day Moving Average | 0.38 EUR |
LUP.F Share Statistics
Avg. Volume (3 month) | 155 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 3.76B |
Float | 1.84B |
Short Ratio | N/A |
% Held by Insiders | 33.42% |
% Held by Institutions | 22.30% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 10.11% |
Operating Margin (ttm) | 13.19% |
Gross Margin | 69.21% |
EBITDA Margin | 23.83% |
Management Effectiveness
Return on Assets (ttm) | 2.10% |
Return on Equity (ttm) | 5.78% |
Income Statement
Revenue (ttm) | 5.98B EUR |
Revenue Per Share (ttm) | 1.72 EUR |
Quarterly Revenue Growth (yoy) | 39.20% |
Gross Profit (ttm) | N/A |
EBITDA | 1.43B EUR |
Net Income Avi to Common (ttm) | 604.81M EUR |
Diluted EPS (ttm) | 0.02 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 5.54B EUR |
Total Cash Per Share (mrq) | 1.56 EUR |
Total Debt (mrq) | 9.19B EUR |
Total Debt/Equity (mrq) | 83.25 EUR |
Current Ratio (mrq) | 1.137 |
Book Value Per Share (mrq) | 2.867 |
Cash Flow Statement
Operating Cash Flow (ttm) | 1.65B EUR |
Levered Free Cash Flow (ttm) | -130700624 EUR |
Profile of Luye Pharma Group Ltd.
Country | Germany |
State | N/A |
City | Yantai |
Address | No. 15 Chuang Ye Road |
ZIP | 264003 |
Phone | N/A |
Website | https://www.luye.cn |
Industry | Drug Manufacturers-General |
Sector(s) | Healthcare |
Full Time Employees | 5005 |
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders. In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.
Q&A For Luye Pharma Group Ltd. Stock
What is a current LUP.F stock price?
Luye Pharma Group Ltd. LUP.F stock price today per share is 0.33 EUR.
How to purchase Luye Pharma Group Ltd. stock?
You can buy LUP.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Luye Pharma Group Ltd.?
The stock symbol or ticker of Luye Pharma Group Ltd. is LUP.F.
Which industry does the Luye Pharma Group Ltd. company belong to?
The Luye Pharma Group Ltd. industry is Drug Manufacturers-General.
How many shares does Luye Pharma Group Ltd. have in circulation?
The max supply of Luye Pharma Group Ltd. shares is 3.76B.
What is Luye Pharma Group Ltd. Price to Earnings Ratio (PE Ratio)?
Luye Pharma Group Ltd. PE Ratio is 16.30000100 now.
What was Luye Pharma Group Ltd. earnings per share over the trailing 12 months (TTM)?
Luye Pharma Group Ltd. EPS is 0.02 EUR over the trailing 12 months.
Which sector does the Luye Pharma Group Ltd. company belong to?
The Luye Pharma Group Ltd. sector is Healthcare.